• The Mydecine Innovations Group portfolio includes a robust portfolio of NCEs (New Chemical Entities) and medicines based on compounds found in psychedelics, including four lead clinical trial drug candidates, as well as digital health solutions
• Through an exclusive partnership with Applied Pharmaceutical Innovations, the company has access to a Health Canada Scheduled 1 Drugs and Substances Dealer’s License
• Mydecine has a five-year master collaboration research agreement with Johns Hopkins University to research novel psychedelic therapies for mental health and addiction disorders
• Research out of Johns Hopkins University has shown promising efficacy data using psilocybin as a smoking cessation treatment with an abstinence rate of 80% at six months
• Mydecine is supplying its lead drug candidate, MYCO-001, for a multi-site NIDA (National Institute on Drug Abuse) grant-funded smoking cessation study, marking the first time in over 50 years that the U.S. government has funded a study of a psychedelic compound
• The company utilizes established drug development infrastructure, and it offers telemedicine and technology solutions through the Mindleap 2.0 platform
• Mydecine is guided by an experienced leadership team and a world-renowned medical & scientific advisory board

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction. Founded in 2020 on the guiding principle that there is a significant unmet need and lack of innovations in the mental health and therapeutic treatment environments, Mydecine is dedicated to efficiently developing innovative first- and second-generation novel therapeutics to treat PTSD, addiction and other mental health disorders. Mydecine’s business model combines clinical trials and data outcome, technology and scientific and regulatory expertise with a focus on psychedelic therapy underpinned by novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine aims to responsibly fast-track the development of new medicines across its platforms, ultimately changing the way we treat mental health disorders. The company seeks to bridge the gap between the needs of patients and what the mental health care system currently provides. Mydecine Innovations Group is headquartered in Denver with international offices in Canada and Europe. Research and Technology The invention and development of novel psychedelic and non-psychedelic molecules for medical use is an important part of Mydecine’s research strategy. The company uses molecules found in nature as building blocks to create improved second-generation drugs. This portfolio of new drugs represents major improvements to existing natural products and synthetics, including enhanced safety, efficacy, stability and dosing, as well as reduced side effects. The goal of creating these improved second-generation compounds is to enable safer, more effective treatments for patients, along with improved management of dosage and drug behavior for clinicians. Mydecine believes the multibillion-dollar market for mental health and addiction disorder medicines will soon be disrupted amid a resurgence of the study into psychedelics and data showing the immense benefits of these forms of medicine. The company currently has four lead drug candidates which include various enhancements such as improved controllability, delivery mechanisms, safety, stability and shelf-life. The drug candidates are in clinical trials or in pre-trial stage as potential treatments to aid PTSD, substance abuse and smoking cessation. Mindleap Health is a wholly owned subsidiary of Mydecine. The Mindleap platform is a virtual community that aims to foster the conscious and responsible adoption of psychedelic medicine into inner wellness. Users access the platform through the Mindleap app. Mindleap provides users with inner wellness resources to assist them in their daily mental-health journeys. The platform also seeks to support the conscious and trustworthy adoption of psychedelics into a widely accepted approach to mental health and inner wellness. Market Outlook The global smoking cessation market is expected to reach $63.99 billion by 2026, growing at a CAGR of 16.9 percent from 2018 to 2026. The market for psychedelic therapeutics is in its very early stages. Estimates of current market value and forecasts of expected value in future years are all over the map. Market forecasts range from $6.5 billion by 2030 with a CAGR of 15 percent, to more than $69 billion as soon as 2025, at a CAGR of 8.2 percent. What is clear is that interest in psychedelic therapeutic drugs is expanding rapidly. Management Team Joshua Bartch is Chief Executive Officer and Chairman of Mydecine Innovations Group. He is an experienced entrepreneur who co-founded AudioTranscriptionist.com and founded Denver-based dispensary Doctors Orders in 2009. He also founded a boutique investment firm that operated throughout the U.S. and Canadian markets. In 2014, Bartch co-founded Cannabase.io, the USA’s most significant and sophisticated legal cannabis wholesale platform. Dr. Rakesh Jetly, OMM, CD, MD, FRCPC, is the Chief Medical Officer of Mydecine. He was formerly Chief of Psychiatry for the Canadian Armed Forces, retiring in 2021 with the rank of colonel after 31 years of service. He began his career as a general duty medical officer and flight surgeon and spent his final 20 years of service as a psychiatrist. He maintains academic appointments at Dalhousie University and The University of Ottawa. He is the inaugural CF Brigadier Jonathan C. Meakins CBE, RCMAC, Chair in Military Mental Health at the Royal Ottawa Hospital. Robert Roscow is Chief Scientific Officer of Mydecine. As a geneticist, he has spent his academic and professional careers looking for valuable and unique medicinal molecules found in nature. His innovations were applied at Canopy Growth and ebbu, where he ran those companies’ genetics divisions. He has leveraged his expertise to maximize industrial production of cannabinoids in a pharmacological context, resulting in multiple patent filings. Damon Michaels is Chief Operating Officer of Mydecine. He previously consulted for various hemp businesses through his company, Emerald Baron. Before that, he served as GM for ebbu, the leading multi-platform cannabinoid research and technology firm based in Colorado. He has held leading roles with multiple large brands throughout the cannabis vertical. He also developed a national snowboard brand. For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• All signs point to gold cooling down, consolidating in the short run before rallying again toward the end of the year and into 2022
• An increase in demand for silver is likely, stemming primarily from the Biden administration’s $2 trillion climate plan
• MONI is investing in a well-diversified acquisition portfolio of income-generating businesses, with precious metals being a key component

The economic uncertainty of the past 18 months has touched almost every aspect of the financial world, including the precious metals space, with prices fluctuating wildly. Although it’s difficult to know what’s in store for gold, silver, and platinum group metals, the forecast looks fairly good. Moon Equity Holdings (OTC: MONI), an investment company that focuses on acquisitions in the fintech, crypto, precious metals, and real estate sectors, is watching market developments closely. “The yellow metal had a strong run last year with an annual price increase of 24%,” reported a “Forbes” article, which was cited as an aggregate of expert opinions in the industry (https://ibn.fm/cmVQM). “On January 2, gold opened at $1,521, and it closed on December 31 at $1,895. This constitutes the best year-over-year growth for gold since 2010. “All signs point to gold cooling down and consolidating in the short run before rallying again toward the end of the year and into 2022,” the article continued, noting that Citigroup predicts a price target of $2,500 by year end and that gold prices would most likely surge if the Fed was forced to raise the federal funds rate to combat rising inflation. “Investors interested in gold will likely want to buy now if they believe the conditions that drove 2020’s bull run — equity market volatility, a weaker dollar, and a low-interest-rate environment — will continue through 2021. It’s important to note, though, that gold prices have fallen in the first couple of months of this year. Forbes also stated that an increase in demand for silver is likely, stemming primarily from the Biden administration’s $2 trillion climate plan. “Silver alloys are used extensively in the production of solar panels and photovoltaic (PV) cells,” they noted. “In fact, in 2019, 100 million ounces of silver was used to construct PV cells worldwide, though business intelligence company CRU Group predicted that to be the peak for silver demand in PV panels.” Furthermore, Forbes also reported that some analysts that some analysts are calling for a $50 per troy ounce price target this year. “It seems likely we’ll see consistent price growth over the next three to four years as the policy environment favors silver.” Finally, Forbes notes how precious metals within the platinum group, including rhodium, ruthenium, osmium, iridium, palladium, and platinum, “are chemically diverse and traditionally represent more volatility than their white and yellow counterparts.  Industry analysts believe that industrial demand for platinum groups is high and showing no signs of slowing down.  Experts suspect an oversupply of platinum — to the tune of up to 670,000 ounces — is expected to keep the price of palladium significantly higher than platinum in 2021.” All this bodes well for Moon Equity Holdings, a company that recently rebranded to reflect a revised business strategy. The company is now focused on investing in a well-diversified acquisition portfolio of income-generating businesses looking to produce long-term gains. Precious metals are a vital component of the company’s growing portfolio. Along with seeking to make an impact on technology, MONI is also focused on leveraging its diverse management team — including its all-female advisory board — to create unique solutions that appeal to a wide range of markets in an effort to enhance the customer experience, create a loyal following and generate repeat business. For more information, visit the company’s website at www.MoonEquityHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to MONI are available in the company’s newsroom at https://ibn.fm/MONI

• StraightUp has incorporated Bear Head Gold Project into its cache of properties, which already include RLX North & South Projects, Belanger Project, and the Ferdinand Gold Project
• The Meen-Dempster Greenstone Belt produced the Golden Patricia, a lucrative mine with rich drilling history
• Bear Head Gold Project historical drilling in 1989 yielded 11.09 g/t Au over 1.79m, 3.98 g/t Au over 2.3m, and 3.08 g/t Au over 2.5m, associated with iron formation and silicified mafic volcanos
• Acquisition of West Cat Mine in the state of Nevada and offers the company expansion opportunities into new areas of exploration

Canada-based mineral exploration and mining property acquisition company StraightUp Resources (CSE: ST) (OTCQB: STUPF) recently acquired the Bear Head Gold Project, comprising 31 mining claims that total 1,944 hectares, located within the Meen-Dempster Greenstone Belt in Western Ontario The belt has a rich drilling history and is famously known for the Golden Patricia, a former gold mine responsible for producing 620,000 ounces of gold, averaging a grade of 15.2 g/t Au, from 1988 to 1997 (https://ibn.fm/1JF90). This project lies proximal to the Bear Head Deformation Zone (“BHDZ”) – a first-order crustal-scale regional fault system extending over 2km wide that extends over 400km from the Pickle Lake Gold Camp. The Dorothy Main gold deposit, owned by Ardiden, is only 1km from StraightUp’s Bear Head Gold Project. The Dorothy Main gold deposit is known for its non-compliant historical resources of 46,600 ounces of gold at 6.17 g/t Au. Also, in Ardiden’s catalog of gold deposits is the Dobie Deposit. The Dobie Deposit is located 7m southeast of the Bear Head Gold Project. Dobie is known for non-compliant historical resources of 53,000 ounces of gold at 5.5 g/t Au. In 1989, historical drilling on the Bear Head Gold Project produced 11.09 g/t Au over 1.79m, 3.98 g/t Au over 2.3m, and 3.08 g/t Au over 2.5m – associated with the iron formation and silicified mafic volcanos. The values above have not been followed up on since the initial drilling in 1989. The Bear Head Gold Project joins a cache of other projects headed by StraightUp in one of Canada’s most fruitful gold mining districts – Red Lake Mining District (https://ibn.fm/RTuxA). This area is renowned for its high-grade gold deposits and is mining-friendly. The other projects StraightUp is working on include:

• RLX North & South Projects – Spanning over 10,000 hectares, RLX North and RLX South are positioned to the southeast of the largest gold deposit in the district (Red Lake Gold Mines – Evolution Mining)
• Belanger Project – Belanger is a 2,000-hectare property that has identified three significant surface exposures of gold, copper, and silver. Early exploration work will focus on the historical sampling of the area. The site also has excellent forest road access from the town of Ear Falls.
• Ferdinand Gold Project – Ferdinand consists of 17 contiguous mining claims that span approximately 7,143 hectares and is located 13km northwest of Slate Falls. According to Mark Brezer, CEO of StraightUp, the Bear Head Gold Project is complementary to the Ferdinand Gold Project.

Another recent acquisition includes the West Cat Mine located in Nevada, U.S. According to StraightUp President and CEO Mark Brezer, Nevada is the second-largest silver producer in the United States, after Alaska, and, in 2014, the state produced roughly 11 million troy ounces, with more than half of that quantity being a byproduct from gold mining. This property is a 20.66-acre land package in an area with high potential that will pave the way for StraightUp to successfully grow and expand into other mining districts and seize new exploration opportunities. “We are extremely excited to begin our expansion into new mining districts and continue to position ourselves among top-quality assets and companies,” Brezer added. For more information, visit the company’s website at www.StraightUpResources.com. NOTE TO INVESTORS: The latest news and updates relating to ST are available in the company’s newsroom at https://ibn.fm/STR

• PLGNF sees 1500% betting handle increase in first half of October with 24.2 million in player betting turnover, up from 1.6 million in September
• Wagering activity up 305,000 bets for first two weeks of October, entire month of September saw 132,000 bets
• Daily player betting turnover approximately $1.6 million per day, up from $53,500 for September
• PLGNF’s proprietary technology runs fast and secure on any browser device without requiring app store download

Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF), a SaaS technology company focused on developing and licensing digital content for the growing global iGaming market, started October with a bang with a betting handle increase of 1500%, surpassing 24.2-million in player betting turnover from 1.6-million for the entire month of September (https://ibn.fm/cYnzA). PLGNF’s player wagering activity was up to 305,000 bets for the first two weeks of October, while the entire month of September saw 132,000 bets – surpassing management’s expectations. “Daily player betting turnover is approximately $1.6 million per day, up from about $53,500 per day for the month of September,” said Darcy Krogh, CEO of Playgon Games. “We are extremely excited about our month-over-month growth.” PLGNF provides a multi-tenant gateway that gives online operators the ability to offer customers innovative iGaming software solutions. The company’s currently available applications include Live Dealer Casino, E-Table Games, and Daily Fantasy Sports. Customers can access the platform without sharing any sensitive customer data via seamless integration at the operator level. In addition, PLGNF’s games can run on any browser device fast and securely – just like any native app and without requiring an app store download. “We knew our proprietary technology was innovative, however the reception we have received from our partners and clients has been unparalleled,” said Krogh. “This is noticeable from the player wagering activity, which has increased to 305,000 bets for the half month of October compared to 132,000 bets for the entire month of September. We are witnessing at least 100% growth across all of our key indicators.” After just four months of being operational, PLGNF onboarded 14 operators, resulting in a massive turnover that exceeded $1,400,000 in August – more than double July’s numbers. In addition, the company plans to build a remote development/engineering team to enable 24/7 development capability in different time zones with a goal of increasing their table count from 15 to 25 live tables by the end of the year. PLGNF’s management team leverages three decades of iGaming experience, with multiple successful exits. All the company’s assets are IP-protected, and the company leverages a favorable market position due to high entry barriers to the rapid-growth industry – forecasted to grow at a CAGR of 12.3% and reach $127.3 billion by 2027, according to Grand View Research (https://ibn.fm/Uwj91). PLGNF offers the first and only Live Dealer Casino streaming live from Las Vegas. In addition, the company brings cutting-edge handheld features and functionality to a new mobile-first generation of gaming enthusiasts that demand a top-tier gaming experience. With a focus on delivering digital games for the iGaming industry and delivering a world-class experience, PLGNF is positioned to be a leader in developing and licensing digital content for the growing global iGaming market. For more information, visit the company’s website at www.Playgon.com. NOTE TO INVESTORS: The latest news and updates relating to PLGNF are available in the company’s newsroom at https://ibn.fm/PLGNF

Date: November 4-6th 2021 Venue: Javits Convention Center, Hall 3A, New York City, NY  Industry professionals in the legalized cannabis and hemp industry are invited to attend The Cannabis World Congress & Business Exposition (CWCBExpo), a business-to-business trade show and conference at the Javits Convention Center, Hall 3A, November 4-6, 2021. The event will be held in person and the convention center requires masks and proof of vaccination. More information can be found under the health and safety section of the venue’s website. The exposition is a three-day event where professionals will be able to participate in a wealth of curated and hosted content, including Inside the Industry: Thought Leadership Series. Geoff Whaling and Matthew Anderson will led this series in a “Talk Show” format, accompanied by influential and informed industry minds, with a different focus on each of the three days of the conference: Day 1: Where We Are Today; Day 2: Challenges and Solutions; Day 3: Where We Are Going. Notable speakers during these three days include, but are not limited to, Christopher “CJ” Wallace, Willie Mack, Faye Coleman, Calvin Frye, Hillary Peckham, Mike Hennesy and more. Conference program emcees for the event feature Keiko Beatie and Kymberly “KymB” Byrnes. Those in attendance at the CWCBExpo are also invited to a unique networking opportunity on November 4, from 5 pm to 7 pm EST. The “Back-to-Business Celebration” will be a chance for industry professionals to continue networking, discussing the trade, or simply unwinding before tackling the remaining two days of the conference. To purchase admittance to the celebration, attendees must be registered for the CWCBExpo. More information on registration can be found at https://cwcbexpo.com/registration_ny/. The CWCBExpo will be a great way to enjoy Cannabis Week (November 1-7), where the entire cannabis industry comes together for a week of learning, sharing, and connecting. For events and discounts during Cannabis Week, visit https://cwcbexpo.com/cannabis-week/ and check out the Cannabis Week Guide (now available and updated regularly). For more information about CWCBExpo, please visit https://cwcbexpo.com/.

The world’s largest and most powerful tech companies –Alphabet (NASDAQ: GOOG), Amazon (NASDAQ: AMZN) and Apple (NASDAQ: AAPL) – are targeting an opportunity in health care that’s just too big to ignore – diabetes. Almost a third of the entire U.S. population – more than 100 million people in this country alone – are living with diabetes or are at high risk for the disease. Diabetes makes it difficult for the body to process sugar (glucose) and can lead to serious health issues and death. With $1 of every $4 of health care costs in the U.S. now spent on caring for people with diabetes, these tech giants are looking to snag a share of the multi-trillion-dollar global diabetes markets through innovation. Managing the disease relies way too much on guesswork and variables – random finger pricks to test blood sugar before trying to accurately adjust insulin dosage is far from perfect science. Plus, a multiplicity of lifestyle choices, like food and exercise, can severely impact people with the disease. Technology is key to helping people with diabetes better manage their disease, and the tech giants are all exploring how they can bring new services and tools to market.

• Alphabet, through its Verily subsidiary, teamed with DexCom Inc. (NASDAQ: DXCM) to bring continuous monitoring hardware to market. DexCom users insert a sensor under the skin and, after the sensor is inserted, a transmitter is snapped into place allowing users to check their readings via a smartphone or watch.
• Amazon makes it easier for people to access their readings via the Alexa voice assistant and promotes blood sugar monitoring devices on its marketplace.
• Apple is working closely with other medical device makers like Dexcom to build integrations with consumer devices like Apple Watch and iPhone.

Tech continues to provide creative solutions to better manage chronic diseases like diabetes. Nemaura Medical Inc. (NASDAQ: NMRD) has developed sugarBEAT(R) – a wearable, non-invasive and flexible continuous glucose monitor patch designed to help people with diabetes and prediabetes manage their glucose levels. sugarBEAT(R) consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with a smartphone app displaying glucose readings at five-minute intervals for periods of up to 24 hours. Users don’t have to draw blood samples or prick their fingers multiples times each day and can wear the patch on whatever days they choose. Other continuous glucose monitor devices on the market must be implanted under the skin. sugarBEAT(R) is the world’s first wearable and disposable monitor which offers the potential to radically change the way people manage their chronic disease conditions. Already cleared in the EU and FDA Pre Market Application (“PMA”) submitted, Nemaura’s patented skin surface blood monitoring technology has allowed the company to create additional products, which are in the pipeline. More information on its technology can be found at www.NemauraMedical.com. Thank goodness, technology is delivering previously unimagined solutions to human frailties and the management of chronic diseases. However, for the record it’s not altruism that’s driving these tech companies, there’s a business opportunity here that’s just too damn big to ignore. For more information, visit the company’s websites at www.NemauraMedical.com or www.MiBoKo.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• Playgon Games is a SaaS technology company focused on licensing its online gaming technology to gaming operators around the world
• The company has recently revealed that it saw player betting turnover rise to $24.2 million as of the first half of October, a 1500% increase relative to September’s $1.6 million
• The pandemic has hastened a switch away from physical casinos and towards online gaming; the online gaming market is now expected to grow to an annual value of $127.3 billion by 2027
• Playgon Games’ business model effectively allows investors to capitalize on overall gaming sector growth while simultaneously forgoing the sector’s elevated player acquisition costs

Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF), a propriety SaaS technology company delivering mobile live dealer technology to online gaming operators globally, has recently revealed that it has surpassed $24.2 million in player betting turnover in the first half of October 2021, up from a mere $1.6 million for the entire month of September (https://ibn.fm/tFsRa). Darcy Krogh, CEO of Playgon Games, commented regarding the results, “Daily player betting turnover is approximately $1.6 million per day, up from about $53,500 per day for the month of September. We are extremely excited about our month over month growth.” He continued, “We knew our proprietary technology was innovative, however the reception we have received from our partners and clients has been unparalleled. This is noticeable from the player wagering activity, which has increased to 305,000 bets for the half month of October compared to 132,000 bets for the entire month of September. We are witnessing at least 100% growth across all of our key indicators.” Playgon Game’s proprietary technology provides digital games for online gambling sites and mobile device apps, with the company licensing its mobile live-dealer technology to online gaming operators worldwide. The pandemic, consumer behaviour, technology, and regulation has hastened an already existing shift away from location-based casinos to online gaming; a recent study has forecast the global online gambling market to reach US$ 127.3 billion by 2027, representing a CAGR of 11.5 percent from 2020 to 2027 (https://ibn.fm/Ryfqv). The shift has primarily been driven by younger, tech-savvy consumer demographics, which has led to the adoption of digital gaming globally. To meet this demand, Playgon has launched a studio with ten gaming tables from which its live dealer streaming video originates. The company’s platform is now live with multiple online casino operators through direct integrations and four aggregator client integrations in South Africa and Europe, with further commitments from other parties still to come. Playgon has also recently revealed plans to expand their current studio to 25 tables in the near term and is working to establish a U.S. and LATAM strategy. In the future, the company will continue to expand licensing of its live dealer games to iGaming operators worldwide under a SaaS license agreement (https://ibn.fm/kH98f). (https://ibn.fm/G6LSC). Thus, and in its role as a B2B software supplier, Playgon Games is able to avoid incurring the elevated play acquisition costs faced by both physical and online gaming entities while simultaneously capitalizing on the growth of the growing online gambling market. As the saying goes in gambling, “the house always wins.” In Playgon Games’ case, they are the house, and the more visitors, the better. For more information, visit the company’s website at www.Playgon.com. NOTE TO INVESTORS: The latest news and updates relating to PLGNF are available in the company’s newsroom at https://ibn.fm/PLGNF

• U.S.-based FingerMotion has been pursuing opportunities to provide text and multimedia message services in China, whose population is expected to exceed 1.4 billion people this year
• FingerMotion is expanding into a third channel of operations with the development of its trademarked big data platform Sapientus, and expects revenues from the tech platform to eventually exceed its SMS and MMS message services
• The company recently reported its Q2 financials, noting a 25 percent YOY quarterly growth in revenues attributed to SMS and MMS services, and an overall quarterly revenue growth to $5.39 million
• China is encouraging development of its insurance industry services, providing increased opportunities for leading global insurers such as Pacific Life
• Pacific Life Reinsurance finalized a contract with FingerMotion for Sapientus’ services earlier this year, strengthening FingerMotion’s position in supporting the insurtech industry

Communications and big data technology platform builder FingerMotion (OTCQX: FNGR) is welcoming signs of growth in its newly released Q2 report. The China-focused enterprise reported quarterly revenue of $5.39 million, which included a 25 percent year-over-year quarterly growth in its short and multimedia messaging (SMS and MMS) business revenue of $0.73 million. “Growth continues unabated with the SMS texting due to our optimized prepayments of bulk inventory purchases. Contributing to the growth and margin expansion was from the subscription plan and the mobile phone sales,” CEO Martin Shen stated in a news release about the financial filing (https://ibn.fm/cU7KK). “These optimized purchase programs and hardware sales and service improved gross profit from 7% to 13%. The Company is seeing strong demand in SMS from our corporate clientele.” Despite the positive news regarding texting and multimedia services, FingerMotion remains committed to improving its bottom line through the development of its trademarked Sapientus big data platform. The company noted a sharp increase in general and administrative expenses tied to research and development as the company continues to build up SMS, MMS and big data services simultaneously. “We are pleased at the strength of our balance sheet which hit a milestone of over $5.0 million in shareholders’ equity. This quarter was more of a transition to greater profitability as more of our initiatives started contributing to gross margin,” Shen stated. “This is the third consecutive quarter of Big Data revenues and we expect it to continue and eventually outpace our existing revenue streams.” During Q1, FingerMotion secured a landmark agreement with Pacific Life Re-insurance to provide Sapientus’ big data prowess as a tool for Pacific Life’s efforts to build its insurance offerings among China’s consumers. China’s population is expected to exceed 1.4 billion people this year, creating the potential of a world-leading base for economic activity. And the country’s leadership has been encouraging further development of the insurance industry, as noted in the China Banking and Insurance Regulatory Commission’s recent statement urging insurers to accelerate their offerings for gig-economy delivery workers, elderly people and children with congenital diseases and medical conditions (https://ibn.fm/nhWPu). But the country’s insurance risk and credit risk evaluation infrastructure is still underdeveloped, which poses a challenge for companies like Pacific Life — one of the world’s top five Insurance companies with $1.1 trillion in life insurance policies and $171 billion in assets (https://ibn.fm/6jhnI). Sapientus delivers predictive algorithms that help clients such as Pacific Life Reinsurance gain insights into consumer activity and risk potential. “This trend will continue and revenue should ramp as the insurtech business starts to develop,” Shen stated. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Lexaria’s THC absorption animal study yielded promising results on the patented DehydraTECH(TM) technology
• It showed that the technology required a shorter time to deliver the same THC levels than concentration-matched controls
• Lexaria believes that through DehydraTECH, it is meeting the needs of medical THC users with its rapid delivery, increased overall THC delivery and high brain tissue delivery

Lexaria Bioscience’s (NASDAQ: LEXX) just-concluded oral tetrahydrocannabinol (“THC”) absorption animal study, THC-A21-1, yielded promising results on the effectiveness of the company’s patented DehydraTECH(TM) drug delivery technology. The study, performed by a leading, independent laboratory, involved 20 male Sprague Dawley rats split into two groups of ten each. It followed the administration of the THC with brain tissues collected at 8 and 24 hours (https://ibn.fm/7S0D0). The study showed that DehydraTECH-THC delivered via oral ingestion required only 15 minutes to dispense THC levels proportional to those achieved at 45 minutes with concentration-matched controls. It also showed that DehydraTECH-THC delivered considerably more THC into the bloodstream compared to standard medium-chain triglyceride (“MCT” or “coconut oil”)- based control formulation, starting from the 2-minute mark onwards. It would then drop rapidly to the same level as the MCT control after 6 hours. While making the announcement, Chris Bunka, Lexaria’s Chief Executive Officer (“CEO”), noted, “THC users today include… medicinal and pharmaceutical users, all of whom need technology that doesn’t rely on harmful delivery methods such as smoking, but still provides rapid onset and high bioavailability which common oral formats do not offer.” Mr. Bunka acknowledged that with DehydraTECH, Lexaria offers a solution that considers medical THC users’ needs. He noted that the findings from this study are proof of the technology’s rapid delivery, increased overall THC delivery, and high brain tissue delivery, all of which are consistent with the needs and wants of medical THC customers. According to Harvard Medical School, medical cannabis use today is largely for pain control. Patients dealing with multiple sclerosis or nerve disorders have cited responding to cannabis treatment a lot better compared to opiates. This alternative has also proven to be more effective without the accompanying addictive or sedating effects linked to opiates. With DehydraTECH, Lexaria is proving that cannabis is not only integral to healthcare going forward but that it can also be administered effectively while still yielding better results for patients. DehydraTECH processing consistently proves its ability to deliver drugs more effectively into the bloodstream and the brain tissue. The THC-A21-1 study is a testament to that and an indication of the tremendous potential that the technology has, not just with THC delivery but also with nicotine, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”), phosphodiesterase inhibitors and anti-viral drugs, among others. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Date: November 2 – 4, 2021 Live Streaming Traders, investors, shareholders, and businesses are invited to attend the Interactive MoneyShow Virtual Expo on November 2-4, 2021. MoneyShow has been organizing conferences and seminars for over 40 years with a 100,000+ community of investors, financial heads, and businesses looking to gain knowledge and guidance about the latest investment tools, financial trends and opportunities from the stalwarts of the financial arena. The event presents a wonderful opportunity for traders and investors to interact with financial leaders and company experts via interactive message boards. The educational videos and articles serve as a source of a huge knowledge base for new traders, shareholders and investors seeking guidance on the management of investments and growth opportunities in the financial trading segment. The Interactive MoneyShow Expo showcases influential speakers who are eminent personas in their niche. Exhibitors can host live presentations and explain their product and service line in the Virtual Exhibit Hall while availing of great discounts and win numerous prizes in different events. This Virtual Exhibit Hall is a tremendous marketing forum where investors from different backgrounds understand your business and you get an opportunity to develop a long-term association with them. Attendees can participate for free to watch the interactive sessions and live presentations by distinguished financial leaders. These dignitaries will discuss who they are adapting their trading and investment plans as per the current market trends. They will also offer their insights and tips into the future course of action on stocks, bonds, and ETFs to options, futures, forex, and more. The interactive sessions offer an in-depth analysis of the current trends so that you can make better trading and investment decisions to enjoy better profits. Inflation will be an important agenda of discussion at the expo where attendees can get valuable guidance and key pointers for managing their investments in the current environment. Presentations will also include detailed explanations on how we can use non-dividend stocks and create our dividend-like cash flow by selling call options. The speaker sessions will be followed by real-life examples as to how to implement option-selling to create a dividend-like cash flow with non-dividend bearing stocks. To know more about the event, please visit https://ibn.fm/Q278k.